This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dow Stocks We Can't Live Without

(, starting Monday and ending Friday, is reviewing all 30 Dow stocks after the index fell 3.1% last month, the steepest drop since February 2009. Six Dow stocks will be featured each day.)

BOSTON ( TheStreet) -- The six Dow stocks ranked halfway between best and worst feature companies that have found their way into most Americans' homes.

AT&T's (T - Get Report) wireless service connects Apple (AAPL) iPhones, Intel's (INTC - Get Report) chips power PCs, and Kraft's (KFT) Cheez Whiz and Oscar Mayer hot dogs provide fuel. All feature "buy" ratings.

>> Dow Stocks: Part 1

>> Dow Stocks: Part 2

Dow stocks are the oft-cited gauge for equity performance in the U.S. and targets for many large-cap fund managers. The simplest way, in theory, for a manager to best the market would be to buy the market but kick out the least attractive Dow stocks.

Picking the top-performing Dow stocks is no easy task. This week we're ranking Dow stocks based on Ratings' proprietary quantitative model. The model takes into account financial strength, volatility, growth potential, performance and dividends to project the stocks that are most likely to perform well over the coming year.

#18. Merck (MRK - Get Report)

Price-to-Earnings: 11.5 (Pharmaceuticals Average: 30.6)

Debt/Capital: 22.8% (Pharmaceuticals Average: 25.3%)

Price-to-Book: 3.53 (Pharmaceuticals Average: 4.32)

Merck is rated "buy" from Ratings' model, yet it carries the lowest ranking among Dow pharmaceutical stocks. Pfizer (PFE) and Johnson & Johnson (JNJ) rank higher because of stronger financials and less volatility. Still, Merck is secure in its own right.

Merck's stock has risen 34% in the past year, surpassing the S&P 500 while maintaining a relatively low beta value of 0.88. A P/E ratio of 11.5 versus the industry average of more than 30 suggests Merck is undervalued. Pfizer and Johnson & Johnson may have the edge in absolute security, but Merck holds its own and is attractive for investors looking to overweight in pharma.
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DIS $118.67 0.61%
INTC $34.45 0.26%
MSFT $53.69 -1.03%
MRK $53.72 0.45%
T $33.45 0.18%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs